92 CHAPTER 3.1 Table 1 (continued). Baseline characteristics compared between RCT populations, RCT-eligible registry population, and RCT-ineligible registry population, stratified by sex. RCT RCT-eligible registry RCT-ineligible registry Females Males p-valueb Females Males p-valueb Females Males pvalueb Depression 4.6% 2.1% *** 6.2%a 4.3%a *** 6.5% 4.6% *** Cancer 4.0% 2.4% *** 0.0%c 0.0%c - 32.4% 32.2% Concomitant medications ACEI or ARB 90.2% 89.8% 100.0%c 100.0%c - 63.7% 74.2% *** Anticoagulant 2.8% 2.6% 40.7% 48.1% *** 33.4% 41.0% *** Antiplatelet 74.7% 79.0% *** 48.2% 46.8% * 45.5% 47.7% ** MRA 47.1% 41.9% *** 38.4% 39.8% * 33.9% 32.7% Betablocker 87.3% 87.5% 100.0% 100.0% - 71.6% 75.0% *** Digitalis glycoside 14.9% 14.7% 17.1% 17.0% 15.7% 13.9% *** Diuretic 78.9% 69.6% *** 81.9% 78.1% *** 81.0% 77.7% *** *p<0.05, **p<0.01, ***p<0.001 a. Data from SwedeHF only b. Comparison between males and females (independent t-test for continuous and ꭓ2 -test for categorical variables) c. Statistical comparisons were not compared because they were part of the criteria for selecting RCT-eligible registry patients Percentages may not add up to 100% due to rounding. SBP, systolic blood pressure; BMI, body mass index; LVEF, left ventricular ejection fraction; CAD, coronary artery disease; TIA, transient ischemic attack; COPD, chronic obstructive pulmonary disease; ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; MRA, mineralocorticoid receptor antagonists; CI, confidence intervals
RkJQdWJsaXNoZXIy MjY0ODMw